CB-183,315

09/01/2014 - "Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection."
01/01/2017 - "Primary Outcomes From a Phase 3, Randomized, Double-Blind, Active-Controlled Trial of Surotomycin in Subjects With Clostridium difficile Infection."
12/01/2017 - "Surotomycin versus vancomycin in adults with Clostridium difficile infection: primary clinical outcomes from the second pivotal, randomized, double-blind, Phase 3 trial."
12/01/2017 - "Enteric microbiome profiles during a randomized Phase 2 clinical trial of surotomycin versus vancomycin for the treatment of Clostridium difficile infection."
10/01/2016 - "Surotomycin versus vancomycin for Clostridium difficile infection: Phase 2, randomized, controlled, double-blind, non-inferiority, multicentre trial."

10/01/2012 - "We report here the in vitro mechanism of action, spontaneous resistance incidence, resistance by serial passage, time-kill kinetics, postantibiotic effect, and efficacy of CB-183,315 in a hamster model of lethal infection. "
11/01/2020 - "difficile infection (CDI) from two Phase 3 clinical trials of surotomycin. "
07/01/2015 - "difficile infection and of a third antimicrobial, surotomycin, to kill C. "

01/01/2017 - "Results of these phase 1 studies support the continued clinical development of surotomycin for the treatment of Clostridium difficile-associated diarrhea. "
06/25/2015 - "Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea."
01/01/2017 - "Surotomycin, a novel, orally administered, cyclic, lipopeptide antibacterial in development for the treatment of Clostridium difficile-associated diarrhea, has demonstrated minimal intestinal absorption in animal models. "
04/01/2016 - "Surotomycin is a bactericidal cyclic lipopeptide in development for treatment ofClostridium difficile-associated diarrhea that has selective and potent activity againstC. "
01/01/2016 - "Surotomycin is a cyclic lipopeptide in development for Clostridium difficile-associated diarrhea. "

12/01/2018 - "Furthermore, since spores contribute to recurrent infection, the ability of surotomycin to suppress spore formation may explain its ability to disrupt the reinfection cycle in the clinical setting."